Cosunter(SZ:300436) Zheng Quan Zhi Xing·2025-05-23 13:14Core Viewpoint - Fujian Guangshentang Pharmaceutical Co., Ltd. is preparing to issue A-shares to specific investors in 2025, with the aim of raising funds for various projects, including innovative drug research and traditional Chinese medicine industrialization. Group 1: Issuance Details - The company plans to issue no more than 47,780,100 A-shares, which will not exceed 30% of the total share capital before the issuance [12][14] - The total amount to be raised is not more than 976.87 million yuan, with funds allocated to innovative drug research, traditional Chinese medicine industrialization, and working capital [15] - The issuance will be conducted through a specific object issuance method, targeting up to 35 specific investors, including qualified institutional investors and natural persons [12][15] Group 2: Legal Compliance and Approval - The board of directors and the shareholders' meeting have approved the issuance plan, ensuring compliance with the Company Law and the company's articles of association [11][16] - The issuance is subject to approval from the Shenzhen Stock Exchange and registration by the China Securities Regulatory Commission [16][17] - The company has conducted thorough legal due diligence to ensure compliance with relevant laws and regulations [6][24] Group 3: Company Structure and Independence - Fujian Guangshentang Pharmaceutical is a legally established joint-stock company with independent operations, assets, and financial management [24][26] - The company has no business relationships with its controlling shareholders that would compromise its independence [25][26] - The controlling shareholder, Aohua Group, holds 17% of the shares, while the actual controllers have a combined voting power of 40.89% [27][28] Group 4: Financial and Operational Integrity - The company has maintained a clean legal record, with no significant violations or administrative penalties in the past three years [20][21] - The financial statements have been audited and comply with accounting standards, ensuring transparency and reliability [20][21] - The company has established a robust governance structure, with independent management and operational capabilities [25][26]